BACKGROUND: HER2+ metastatic breast cancer (MBC) is a poor prognosis disease, unusually curable. To date, no predictive factors have been clearly correlated with long-term response to anti-HER2 agents. METHODS: 54 HER2+ MBC patients treated with HER2 targeted therapy as first line treatment were analysed: 40 with a time to progression longer than 3 years in Long Responders (LR) group and 14 with a progression disease within one year of anti-HER2 therapy in a control group named Early Progressors (EP). The expression of 770 genes and 13 molecular pathways were evaluated using Nanostring PanCancer pathway panel performed on FFPE BC tissues. RESULTS: Considering baseline patients and tumor characteristics, EP women had more CNS spread and more metastatic burden of disease compared to LR (p > 0.05). Gene expression analysis identified 30 genes with significantly different expression in the two cohorts; five were driver genes (BRCA1, PDGFRA, AR, PHF6 and MSH2). The majority of these genes were over-expressed, mainly in LR patients, and encoded growth factors, pro- or anti-inflammatory interleukins and DNA repair factors. Only four genes were down regulated, all in EP group (TNFSF10, CACNG1, IL20RB and BRCA1). Most of these genes were involved in MAPK and PI3K pathways. MAPK pathway was differently expressed between LR and EP (p = 0.05). PI3K was the only pathway overexpressed in EP patients. CONCLUSIONS: Whole genome expression analysis comparing LR vs. EP identified a group of genes that may predict more favourable long-term outcomes. Up-regulation of MAPK and down-regulation of PI3K pathway could be a positive predictive factors. Further clinical implications are warranted. ABBREVIATIONS: BC: breast cancer; MBC: metastatic breast cancer; LR: long responder; EP: early progressor; FFPE: formalin-fixed paraffin-embedded; CNS: central nervous system; PFS: progression free survival; OS: overall survival.
BACKGROUND:HER2+ metastatic breast cancer (MBC) is a poor prognosis disease, unusually curable. To date, no predictive factors have been clearly correlated with long-term response to anti-HER2 agents. METHODS: 54 HER2+ MBCpatients treated with HER2 targeted therapy as first line treatment were analysed: 40 with a time to progression longer than 3 years in Long Responders (LR) group and 14 with a progression disease within one year of anti-HER2 therapy in a control group named Early Progressors (EP). The expression of 770 genes and 13 molecular pathways were evaluated using Nanostring PanCancer pathway panel performed on FFPE BC tissues. RESULTS: Considering baseline patients and tumor characteristics, EP women had more CNS spread and more metastatic burden of disease compared to LR (p > 0.05). Gene expression analysis identified 30 genes with significantly different expression in the two cohorts; five were driver genes (BRCA1, PDGFRA, AR, PHF6 and MSH2). The majority of these genes were over-expressed, mainly in LR patients, and encoded growth factors, pro- or anti-inflammatory interleukins and DNA repair factors. Only four genes were down regulated, all in EP group (TNFSF10, CACNG1, IL20RB and BRCA1). Most of these genes were involved in MAPK and PI3K pathways. MAPK pathway was differently expressed between LR and EP (p = 0.05). PI3K was the only pathway overexpressed in EP patients. CONCLUSIONS: Whole genome expression analysis comparing LR vs. EP identified a group of genes that may predict more favourable long-term outcomes. Up-regulation of MAPK and down-regulation of PI3K pathway could be a positive predictive factors. Further clinical implications are warranted. ABBREVIATIONS: BC: breast cancer; MBC: metastatic breast cancer; LR: long responder; EP: early progressor; FFPE: formalin-fixed paraffin-embedded; CNS: central nervous system; PFS: progression free survival; OS: overall survival.
Entities:
Keywords:
HER2 positive; PanCancer; gene expression profile; long responders; metastatic breast cancer; trastuzumab
Authors: Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend Journal: Nature Date: 2002-01-31 Impact factor: 49.962
Authors: M V Dieci; A Prat; E Tagliafico; L Paré; G Ficarra; G Bisagni; F Piacentini; D G Generali; P Conte; V Guarneri Journal: Ann Oncol Date: 2016-08-02 Impact factor: 32.976
Authors: Pooja Murthy; Kelley M Kidwell; Anne F Schott; Sofia D Merajver; Jennifer J Griggs; Jeffrey D Smerage; Catherine H Van Poznak; Max S Wicha; Daniel F Hayes; N Lynn Henry Journal: Breast Cancer Res Treat Date: 2016-02-13 Impact factor: 4.872
Authors: D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman Journal: Am J Hum Genet Date: 1998-03 Impact factor: 11.025
Authors: Sandra M Swain; José Baselga; Sung-Bae Kim; Jungsil Ro; Vladimir Semiglazov; Mario Campone; Eva Ciruelos; Jean-Marc Ferrero; Andreas Schneeweiss; Sarah Heeson; Emma Clark; Graham Ross; Mark C Benyunes; Javier Cortés Journal: N Engl J Med Date: 2015-02-19 Impact factor: 91.245
Authors: Y Eralp; D Derin; Y Ozluk; E Yavuz; N Guney; P Saip; M Muslumanoglu; A Igci; S Kücücük; M Dincer; A Aydiner; E Topuz Journal: Ann Oncol Date: 2007-11-15 Impact factor: 32.976
Authors: Inês Carvalho; Fernanda Milanezi; Albino Martins; Rui M Reis; Fernando Schmitt Journal: Breast Cancer Res Date: 2005-08-01 Impact factor: 6.466
Authors: D A Yardley; D Tripathy; A M Brufsky; H S Rugo; P A Kaufman; M Mayer; J Magidson; B Yoo; C Quah; M Ulcickas Yood Journal: Br J Cancer Date: 2014-04-17 Impact factor: 7.640
Authors: Debora de Melo Gagliato; Denis Leonardo Fontes Jardim; Mario Sergio Pereira Marchesi; Gabriel N Hortobagyi Journal: Oncotarget Date: 2016-09-27
Authors: Karsten Kleo; Vladimir M Jovanovic; Alexander Arndold; Annika Lehmann; Hedwig Lammert; Erika Berg; Hannah Harloff; Christoph Treese; Michael Hummel; Severin Daum Journal: J Cancer Res Clin Oncol Date: 2022-03-05 Impact factor: 4.553
Authors: Alexey A Leontovich; Mohammad Jalalirad; Jeffrey L Salisbury; Lisa Mills; Candace Haddox; Mark Schroeder; Ann Tuma; Maria E Guicciardi; Luca Zammataro; Mario W Gambino; Angela Amato; Aldo Di Leonardo; James McCubrey; Carol A Lange; Minetta Liu; Tufia Haddad; Matthew Goetz; Judy Boughey; Jann Sarkaria; Liewei Wang; James N Ingle; Evanthia Galanis; Antonino B D'Assoro Journal: Breast Cancer Res Date: 2018-09-04 Impact factor: 6.466